Increased Afterload Augments Sunitinib-Induced Cardiotoxicity in an Engineered Cardiac Microtissue Model

Sunitinib, a multitargeted oral tyrosine kinase inhibitor, used widely to treat solid tumors, results in hypertension in up to 47% and left ventricular dysfunction in up to 19% of treated individuals. The relative contribution of afterload toward inducing cardiac dysfunction with sunitinib treatment...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JACC Basic Transl Sci
Egile Nagusiak: Truitt, Rachel, Mu, Anbin, Corbin, Elise A., Vite, Alexia, Brandimarto, Jeffrey, Ky, Bonnie, Margulies, Kenneth B.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2018
Gaiak:
PRECLINICAL RESEARCH
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6059907/
https://ncbi.nlm.nih.gov/pubmed/30062212
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2017.12.007
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak